[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496259":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":34,"locations":45,"responsibleParty":63,"collaborators":33,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":33,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":33,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":48,"whyStopped":33,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Levofloxacin group","EXPERIMENTAL","Levofloxacin 200mg twice per day is administrated.",[13],"Drug: Levofloxacin",{"label":15,"type":16,"description":17,"interventionNames":18},"Levofloxacin simulant group","PLACEBO_COMPARATOR","Levofloxacin simulant 200mg twice per day is administrated.",[19],"Drug: Levofloxacin simulant",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Levofloxacin","Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.",[9],[27],"Intravenous Thrombolysis",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Levofloxacin simulant","Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.",[15],[27],null,[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Yi Yang, MD, PhD","CONTACT","13756661217","0086","doctoryangyi@163.com",{"name":42,"role":37,"phone":43,"phoneExt":39,"email":44},"Zhen-Ni Guo, MD, PhD","18186872986","zhen1ni2@163.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"First Hospital of Jilin University","RECRUITING","Changchun","Jilin","130000","China","CN",{"type":55,"coordinates":56},"Point",[57,58],125.32278,43.88,{"lat":58,"lon":57},[61],{"name":36,"role":37,"phone":62,"phoneExt":33,"email":40},"86-18186870008",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","Yi Yang","Associated Dean of First Hospital of Jilin University","100496259","safety-and-efficacy-of-levofloxacin-combined-with-intravenous-thrombolysis-for-acute-ischemic-stroke-100496259",false,"NCT05741905","Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Acute ischemic stroke patients underwent intravenous thrombolysis, treated with ateplase (0.9mg\u002Fkg)\n3. mRS≤1 before stroke onset, NIHSS ≥ 5 and ≤ 15，la (NIHSS) level of consciousness \\\u003C 1\n\nExclusion Criteria:\n\n1. Endovascular treatment\n2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days;\n3. Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc\\>430ms, female: QTc\\>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases;\n4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml\u002Fmin; Urea nitrogen≥ 20mg\u002FdL;\n5. Concurrent infection;\n6. Fasting blood glucose lower than 3.9 mmol\u002FL;\n7. Patients with symptomatic intracranial hemorrhage confirmed by clinical signs and imaging before randomization;\n8. Patients allergy to fluoroquinolones or other antibiotics;\n9. Patients with a life expectancy less than 3 months or patients unable to complete the study for other reasons;\n10. Not willing to be followed up or poor treatment compliance;\n11. Patients who are participating in other clinical studies, or have participated in other clinical studies within 3 months before enrollment, or have participated in this study;\n12. Other conditions not suitable for enrollment.","ALL","18 Years","75 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"NA","The purpose of this study is to determine the efficacy and safety of levofloxacin combined with intravenous thrombolysis in treating acute ischemic stroke",[84],"Acute Ischemic Stroke",[86,87,23],"Acute ischemic stroke","Intravenous thrombolysis","2024-10-01",{"date":90,"type":91},"2024-10-02","ACTUAL",{"date":93,"type":91},"2023-06-01",{"date":95,"type":78},"2024-12-31",{"name":65,"class":6},1]